MAM
CSTL icon

Meeder Asset Management’s Castle Biosciences CSTL Stock Holding History

Meeder Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.7K Buy
994
+607
+157% +$13.5K ﹤0.01% 575
2026
Q1 		$9.5K Buy
+387
New +$12.7K ﹤0.01% 706
2020
Q4 		– Sell
-1,294
Closed -$66K – 1949
2020
Q3 		$66K Buy
+1,294
New +$57.6K ﹤0.01% 897

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meeder Asset Management's CSTL Position: Q2 2026 in Review

Meeder Asset Management increased its Castle Biosciences (CSTL) stake by 157% in Q2 2026, buying an estimated $13.5K and bringing the position to 994 shares worth $23.7K. The position accounts for ﹤0.01% of the portfolio, ranked #575.

Meeder Asset Management first reported a position in CSTL in Q3 2020 and has held it in 3 quarters since. The position peaked at $66K in Q3 2020. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Meeder Asset Management held 994 shares of Castle Biosciences worth $23.7K as of Q2 2026.
  • Meeder Asset Management bought 607 Castle Biosciences shares in Q2 2026, an estimated $13.5K.
  • Castle Biosciences made up ﹤0.01% of Meeder Asset Management's portfolio in Q2 2026, its #575 holding.
  • Meeder Asset Management first reported a position in Castle Biosciences in Q3 2020 and has held it in 3 quarters since.
  • Meeder Asset Management's Castle Biosciences position peaked at $66K in Q3 2020.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.